Vogt-Koyanagi-Harada's (VKH) disease is reported to be closely associated with the HLA class II antigen, HLA-DR4. Serologically defined DR4 is further divided into 11 alleles by molecular HLA genotyping. However, no study of HLA-DNA typing of VKH patients has been reported. To The HLA class II region in the major histocompability complex (MHC) on human chromosome 6 encodes the heterodimeric (a and ,B chains) glycoproteins expressed on the surface of antigen-presenting cells in the immune system. The T cell receptor interacts with a complex formed by the antigenic peptide fragment bound by the HLA molecule on the antigen-presenting cells. On the basis of x ray crystallographic analysis of the HLA class I antigen, HLA-A2, the outermost domains of each class II chain are predicted to fold together to form a groove and cleft, and so appear to function by trapping the antigenic peptide fragment into a groove for the presentation to antigenic-restricted T cells in the initiation of immune response. The genetic polymorphism of class II molecules is known to be clustered into the discrete regions of the 13 
genetic mechanism underlying the susceptibility/resistance to VKH disease, HLA-DNA typing of DR antigens (DRB1 genotyping) by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was performed. It was found that DRB1*0405 showed a significant association with VKH disease compared with the healthy controls (corrected p value <lx and that all the patients had DRB1*0405 and/or DRB1*0410. The (Table 1) .
HLA-DR4, DR53, and DQ4 were significantly increased in the VKH patients compared with the healthy controls (DR4:RR= 120 8, pc<lx10-5, DR53:RR=48 2, pc<1x103, DQ4:RR=11-6, pc<1x10-5). It was noteworthy that DR4 and DR53 were present in 100% of the VKH patients examined.
On the other hand, HLA-DR6 and DR52 were negatively associated with the VKH patients compared with the healthy controls by p value, but these differences were not statistically significant after correction of the p values (DR6:RR=0-1, p<5x10-2, DR52:RR=0 27, p<S x 10-'). pc< I x 10-5) ( Table 2 ).
Numaga et al23 also investigated the relation between VKH disease and HLA-DR4 at the molecular level by the PCR-SSO method. However, the number of SSO probes they used was limited and could not allow full DRB1*04 genotyping. They selected three probes including the nucleotide sequence ofDRB1*0405. Probe 1 was common in all the DR4 genes, probe 2 represented the amino acid sequence specific for DRB1*0404, 0405, 0408, and probe 3 corresponded to the third AHVR of DRB1*0404, 0405, 0408, 0101, and 1402. So these three probes cannot cover all the genetic variations of 11 DRB1*04 alleles, although theyfound that all but one patients (19 of 20) had a specific sequence encoding amino acids 70 and 71 of the DR(3 chain detected by probe 3. In our studies, there was no significant difference in the frequencies of DRB1*0101 and DRB1*1402 in the VKH patients when compared with 70 healthy controls (Table 2) . Consequently, there was not enough of their data to discuss which DRB1*04 allele could be attributed to susceptibility to VKH disease.
We performed the complete DRB1 genotyping by the PCR-RFLP method and found that all the patients had DRB1*04 alleles and that DRB1*0405 was significantly associated with VKH disease (Table 2 ). To confirm the significant association with DRB1*0405 in VKH patients, we compared the DRB1*04 suballelic frequencies of 40 VKH patients with those of 55 DRB1*04 (DR4) positive healthy controls (Table 3 ). DRB1*0405 was again significantly increased when compared with the DR4 positive healthy controls. In addition, all the VKH patients who did not have DRB1*0405 possessed DRB1*0410, suggesting that the susceptibility to VKH disease was determined by the presence of the shared functional epitope common to DRB1*0405 and DRB1*0410. The published amino acid sequences of the polymorphic ,3 domains of the DRB1 genes show that the amino acid specific for both DRB1*0405 and 0410 is serine (Ser, a neutral amino acid) at position 57 instead of aspartic acid (Asp, an acidic amino acid) as in many other DRB1 alleles (Table 4) We demonstrated that DRBl*0405 and DRB1*0410 were closely associated with VKH disease. The distribution of DR4 associated alleles is known to be different among races, so predicting that the incidence of VKH disease might be less prevalent in white populations where DRB1*0405 and DRB1*0410 are rare.28
In fact, VKH disease occurs frequently in orientals, especially Japanese, American Indians and Hispanic people, but is rare in white people, revealing that the susceptible locus of VKH disease may be strongly associated with some ethnic specific allele(s).
Strong linkage disequilibrium exists between HLA-DR and DQ molecules and differs among races.29 At present, the involvement of the HLA-DQ molecule cannot be excluded because DRB1*0405, the most significant increased allele in the VKH patients, is in a close linkage disequilibrium with DQB1*04 (DQ4) in Japanese. In fact, serologically defined DQ4 is also significantly increased in VKH patients when compared with healthy controls (Table 1) .
To address this issue, HLA-DQ genotyping of Japanese VKH patients is now being performed in our laboratory. In this study, it was suggested that Ser at position 57 of DRBl gene was closely associated with VKH disease and further HLA-DQ genotyping will be important to understand molecular mechanism for the susceptibility to VKH disease. In order to understand the molecular relation between the immunogenetic mechanism and pathogenesis of VKH disease, analysis of the peptide sequence derived from foreign or self antigens responsible for the development of the disease, for its presentation by the HLA DRB1*0405 or DRB1*0410 molecule, and also for the effects of these particular HLA class II alleles on T cell receptors during T cell ontogeny will be necessary.
